Case series of intravenous thrombolysis for acute ischemic stroke in confirmed COVID-19 patients: single-centre experience

BACKGROUND: Coronavirus disease 2019 (COVID-19) not only caused a large surge of respiratory infections, it also had a potential association with and increases the risk of stroke. The pandemic has certainly provided new challenges and opportunities in the management of acute ischemic stroke (AIS); h...

Descripción completa

Detalles Bibliográficos
Autores principales: Alwahdy, Ahmad Sulaiman, Margaretha, Ika Yulieta, Pramesti, Kenyo Sembodro, Hamro, Nailaufar, Yuzella, Viska, Nasution, Fitriani, Mappalilu, Arfan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743695/
https://www.ncbi.nlm.nih.gov/pubmed/35035211
http://dx.doi.org/10.1186/s41983-021-00434-w
Descripción
Sumario:BACKGROUND: Coronavirus disease 2019 (COVID-19) not only caused a large surge of respiratory infections, it also had a potential association with and increases the risk of stroke. The pandemic has certainly provided new challenges and opportunities in the management of acute ischemic stroke (AIS); however, data regarding outcomes of intravenous tissue plasminogen activator (IV TPA) administration in stroke patients with COVID-19 remains limited. CASE PRESENTATION: Three AIS patients with confirmed COVID-19 treated using IV tPA. One case had excellent outcome, while the other cases showed unfavorable results. The risk–benefit ratio of IV TPA in COVID-19 remains unclear. CONCLUSION: In this article, we discuss the possible explanation behind these different outcomes. Although IV tPA could not cure COVID-19, we suggest that its administration should not be delayed in AIS patients with COVID-19.

Ejemplares similares